Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
EW Analyst Ratings
Moderate Buy
16 Buy
10 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
EW Stock 12 Month Forecast
Average Price Target
$88.70
▲(14.05% Upside)
| Highest Price Target$101.00 | Average Price Target$88.70 | Lowest Price Target$80.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$83→$86
Buy
10.58%
Upside
Upgraded
09/30/25
AI Generated ArticleAI Generated Article
Stifel Nicolaus
$95→$85
Buy
9.30%
Upside
Reiterated
09/22/25
Barclays
$90→$95
Buy
22.16%
Upside
Reiterated
09/19/25
Piper Sandler
$90
Buy
15.73%
Upside
Reiterated
09/15/25
William Blair
―
Buy
―
Reiterated
08/28/25
Citi
$95
Buy
22.16%
Upside
Reiterated
08/27/25
Leerink Partners
$85
Hold
9.30%
Upside
Reiterated
08/27/25
Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A) and Edwards Lifesciences (NYSE: EW)We see an attractive setup for PEN into the conference based on the STORM-PE results potentially representing an important commercial catalyst for the company's mechanical thrombectomy business in pulmonary embolism (PE) and venous thromboembolism (VTE) broadly.
RBC Capital
$89
Buy
14.44%
Upside
Reiterated
08/19/25
Argus Research
―
Buy
―
Reiterated
08/11/25
Argus Research Remains a Buy on Edwards Lifesciences (EW)We like the growth opportunities for Edwards Lifesciences Corp. (NYSE: EW), as it is a leader in the fast-growing markets for the repair and replacement of heart valves. Edwards makes devices that are implanted through catheter-based minimally invasive procedures and through surgery. These solutions repair the heart’s aortic, mitral, and tricuspid valves. Edwards has substantial growth opportunities. Its transcatheter aortic valve replacement (TAVR) devices are focused on a large addressable market. The global TAVR market is projected to grow around 7% CAGR to $10 billion-$11 billion by 2030, according to market intelligence sources. Edwards’ devices treat aortic stenosis (AS), a narrowing of the aortic valve due to calcium deposits that prevents valve leaflets from opening and closing properly, impeding blood flow.
Wells Fargo
$84→$88
Buy
13.15%
Upside
Reiterated
08/07/25
Robert W. Baird
$79→$81
Hold
4.15%
Upside
Reiterated
08/07/25
J.P. Morgan
―
Hold
―
Reiterated
08/06/25
Daiwa
$89
Buy
14.44%
Upside
Upgraded
07/29/25
BTIG
$100
Buy
28.58%
Upside
Upgraded
07/29/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$83→$86
Buy
10.58%
Upside
Upgraded
09/30/25
AI Generated ArticleAI Generated Article
Stifel Nicolaus
$95→$85
Buy
9.30%
Upside
Reiterated
09/22/25
Barclays
$90→$95
Buy
22.16%
Upside
Reiterated
09/19/25
Piper Sandler
$90
Buy
15.73%
Upside
Reiterated
09/15/25
William Blair
―
Buy
―
Reiterated
08/28/25
Citi
$95
Buy
22.16%
Upside
Reiterated
08/27/25
Leerink Partners
$85
Hold
9.30%
Upside
Reiterated
08/27/25
Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A) and Edwards Lifesciences (NYSE: EW)We see an attractive setup for PEN into the conference based on the STORM-PE results potentially representing an important commercial catalyst for the company's mechanical thrombectomy business in pulmonary embolism (PE) and venous thromboembolism (VTE) broadly.
RBC Capital
$89
Buy
14.44%
Upside
Reiterated
08/19/25
Argus Research
―
Buy
―
Reiterated
08/11/25
Argus Research Remains a Buy on Edwards Lifesciences (EW)We like the growth opportunities for Edwards Lifesciences Corp. (NYSE: EW), as it is a leader in the fast-growing markets for the repair and replacement of heart valves. Edwards makes devices that are implanted through catheter-based minimally invasive procedures and through surgery. These solutions repair the heart’s aortic, mitral, and tricuspid valves. Edwards has substantial growth opportunities. Its transcatheter aortic valve replacement (TAVR) devices are focused on a large addressable market. The global TAVR market is projected to grow around 7% CAGR to $10 billion-$11 billion by 2030, according to market intelligence sources. Edwards’ devices treat aortic stenosis (AS), a narrowing of the aortic valve due to calcium deposits that prevents valve leaflets from opening and closing properly, impeding blood flow.
Wells Fargo
$84→$88
Buy
13.15%
Upside
Reiterated
08/07/25
Robert W. Baird
$79→$81
Hold
4.15%
Upside
Reiterated
08/07/25
J.P. Morgan
―
Hold
―
Reiterated
08/06/25
Daiwa
$89
Buy
14.44%
Upside
Upgraded
07/29/25
BTIG
$100
Buy
28.58%
Upside
Upgraded
07/29/25
Best Analysts Covering Edwards Lifesciences
1 Month
xxx
Success Rate
13/18 ratings generated profit
Average Return
+2.94%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 72.22% of your transactions generating a profit, with an average return of +2.94% per trade.
3 Months
xxx
Success Rate
15/22 ratings generated profit
Average Return
+2.12%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.18% of your transactions generating a profit, with an average return of +2.12% per trade.
1 Year
Success Rate
22/32 ratings generated profit
Average Return
+11.06%
reiterated a buy rating 2 months ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +11.06% per trade.
2 Years
xxx
Success Rate
19/32 ratings generated profit
Average Return
+9.60%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 59.38% of your transactions generating a profit, with an average return of +9.60% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
EW Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
0
0
0
0
0
Buy
16
16
26
34
36
Hold
19
15
21
23
22
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
31
47
57
58
Each month's total comprises the sum of three months' worth of ratings.
EW Financial Forecast
EW Stock Forecast FAQ
What is EW’s average 12-month price target, according to analysts?
Based on analyst ratings, Edwards Lifesciences’s 12-month average price target is 88.70.
What is EW’s upside potential, based on the analysts’ average price target?
Edwards Lifesciences has 14.05% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is EW a Buy, Sell or Hold?
Edwards Lifesciences has a consensus rating of Moderate Buy which is based on 16 buy ratings, 10 hold ratings and 0 sell ratings.
What is Edwards Lifesciences’s price target?
The average price target for Edwards Lifesciences is 88.70. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $101.00 ,the lowest forecast is $80.00. The average price target represents 14.05% Increase from the current price of $77.77.
The highest analyst price target is $101.00 ,the lowest forecast is $80.00. The average price target represents 14.05% Increase from the current price of $77.77.
What do analysts say about Edwards Lifesciences?
Edwards Lifesciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 26 Wall Streets Analysts.
How can I buy shares of EW?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.